Colestase Intra-Hepática da Gravidez Casuística da Maternidade do Hospital Dona Estefânia

Introdução: A CIHG é uma patologia que surge habitualmente na 2ª metade da gestação e tem carácter recorrente. Objectivo: Determinar a incidência da patologia, o outcome obstétrico e fetal das grávidas com diagnóstico de CIHG. Métodos: Estudo retrospectivo, de Janeiro/2004 a Outubro/2010. Variáveis estudadas: referentes à grávida (idade, antecedentes obstétricos), gravidez (idade gestacional ao diagnóstico, conduta clínica) e parto (incluindo complicações intra-parto), bem como complicações maternas/fetais pós-parto. Resultados: 57 grávidas (incidência 0,41% - 57/14053), com idade média 31,5±5,8 anos, 56,1% nulíparas e 36% com antecedentes pessoais de CIHG. A sintomatologia surgiu em média às 33,8±3,1 semanas (S). Em 55,9% procedeu-se a internamento imediato (IG 35±2,7S), 44,1% foram vigiadas em ambulatório (IG 32,1±3S), em média durante 3,7±1,9S. 57,9% necessitaram de terapêutica médica. Em 65% procedeu-se a indução do trabalho de parto, na maioria dos casos pela idade gestacional (≥37S); 17,5% iniciaram trabalho de parto espontâneo (70% pré-termo). Cesariana em 38,6%, das quais 72,7% em âmbito de urgência. 22,2% de casos de CTG intra-parto não tranquilizador e em 15,8%,líquido amniótico meconial. A idade gestacional média ao nascimento foi 36,2±2,2S; 38,6% RN prematuros (2/3 iatrogénicos), tendo-se verificado 1 caso de hemorragia pós-parto, 3 de febre puerperal e 1 de asfixia neonatal grave. Discussão: Patologia de baixa incidência, recorrente, atingindo frequentemente grávidas de grupo etário superior. Associa-se a marcada iatrogenia, prematuridade, risco de distócia e sofrimento fetal intra-parto. Estes dados estão de acordo com a literatura.

Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group

BACKGROUND: Few randomised studies have compared antiandrogen intermittent hormonal therapy (IHT) with continuous maximal androgen blockade (MAB) therapy for advanced prostate cancer (PCa). OBJECTIVE: To determine whether overall survival (OS) on IHT (cyproterone acetate; CPA) is noninferior to OS on continuous MAB. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 randomised trial compared IHT and continuous MAB in patients with locally advanced or metastatic PCa. INTERVENTION: During induction, patients received CPA 200 mg/d for 2 wk and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH; triptoreline 11.25 mg) analogue plus CPA 200 mg/d. Patients whose prostate-specific antigen (PSA) was <4 ng/ml after 3 mo of induction treatment were randomised to the IHT arm (stopped treatment and restarted on CPA 300 mg/d monotherapy if PSA rose to ≥20 ng/ml or they were symptomatic) or the continuous arm (CPA 200 mg/d plus monthly LHRH analogue). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome measurement was OS. Secondary outcomes included cause-specific survival, time to subjective or objective progression, and quality of life. Time off therapy in the intermittent arm was recorded. RESULTS AND LIMITATIONS: We recruited 1045 patients, of which 918 responded to induction therapy and were randomised (462 to IHT and 456 to continuous MAB). OS was similar between groups (p=0.25), and noninferiority of IHT was demonstrated (hazard ratio [HR]: 0.90; 95% confidence interval [CI], 0.76-1.07). There was a trend for an interaction between PSA and treatment (p=0.05), favouring IHT over continuous therapy in patients with PSA ≤1 ng/ml (HR: 0.79; 95% CI, 0.61-1.02). Men treated with IHT reported better sexual function. Among the 462 patients on IHT, 50% and 28% of patients were off therapy for ≥2.5 yr or >5 yr, respectively, after randomisation. The main limitation is that the length of time for the trial to mature means that other therapies are now available. A second limitation is that T3 patients may now profit from watchful waiting instead of androgen-deprivation therapy. CONCLUSIONS: Noninferiority of IHT in terms of survival and its association with better sexual activity than continuous therapy suggest that IHT should be considered for use in routine clinical practice.